|
π
|
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
57 auth.
C. Furberg,
J. Wright,
B. Davis,
J. Cutler,
M. Alderman,
H. Black,
W. Cushman,
R. Grimm,
L. Haywood,
F. Leenen,
S. Oparil,
J. Probstfield,
P. Whelton,
C. Nwachuku,
D. Gordon,
...
M. Proschan,
Paula Einhom,
C. Ford,
L. Piller,
I. K. Dunn,
D. Goff,
S. Pressel,
Judy Bettencourt,
Barbara DeLeon,
Lara M. Simpson,
J. Blanton,
T. Geraci,
Sandra M. Walsh,
C. Nelson,
Mahboob Rahman,
Anne Juratovac,
R. PospΓΕ‘il,
L. Carroll,
Sheila Sullivan,
J. Russo,
G. Barone,
Rudy Christian,
S. Feldman,
T. Lucente,
D. Calhoun,
Kimo Jenkins,
Peggy McDowell,
Janice Johnson,
C. Kingry,
J. Alzate,
K. Margolis,
Leslie Ann Holland-Klemme,
B. Jaeger,
J. Williamson,
G. Louis,
Pamela Ragusa,
A. Williard,
R. L. Ferguson,
J. Tanner,
J. Eckfeldt,
R. Crow,
J. Pelosi
|
12 |
2002 |
12
π
|
|
π
|
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
18 auth.
W. Cushman,
C. Ford,
J. Cutler,
K. Margolis,
B. Davis,
R. Grimm,
H. Black,
B. Hamilton,
J. Holland,
C. Nwachuku,
...
V. Papademetriou,
J. Probstfield,
J. Wright,
M. Alderman,
R. Weiss,
L. Piller,
Judy Bettencourt,
Sandra M. Walsh
|
9 |
2002 |
9
π
|
|
π
|
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
18 auth.
Mahboob Rahman,
S. Pressel,
B. Davis,
C. Nwachuku,
J. Wright,
P. Whelton,
J. Barzilay,
V. Batuman,
J. Eckfeldt,
M. Farber,
...
Mario A. Henriquez,
N. Kopyt,
G. Louis,
M. Saklayen,
Carol W Stanford,
C. Walworth,
H. Ward,
T. Wiegmann
|
8 |
2005 |
8
π
|
|
π
|
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.
15 auth.
J. Wright,
W. Cushman,
B. Davis,
J. Barzilay,
Pedro J. Colon,
D. Egan,
T. Lucente,
C. Nwachuku,
S. Pressel,
F. Leenen,
...
J. Frolkis,
R. Letterer,
Sandra M. Walsh,
J. Tobin,
Grant E Deger
|
8 |
2001 |
8
π
|
|
π
|
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
17 auth.
P. Whelton,
J. Barzilay,
W. Cushman,
B. Davis,
Ekambaram Iiamathi,
J. Kostis,
F. Leenen,
G. Louis,
K. Margolis,
D. E. Mathis,
...
J. Moloo,
C. Nwachuku,
D. Panebianco,
D. Parish,
S. Pressel,
D. Simmons,
U. Thadani
|
8 |
2005 |
8
π
|
|
π
|
Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate
19 auth.
Mahboob Rahman,
S. Pressel,
B. Davis,
C. Nwachuku,
J. Wright,
P. Whelton,
J. Barzilay,
V. Batuman,
J. Eckfeldt,
M. Farber,
...
S. Franklin,
Mario A. Henriquez,
N. Kopyt,
G. Louis,
M. Saklayen,
Carol W Stanford,
C. Walworth,
H. Ward,
T. Wiegmann
|
7 |
2006 |
7
π
|
|
π
|
Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
19 auth.
F. Leenen,
C. Nwachuku,
H. Black,
W. Cushman,
B. Davis,
Lara M. Simpson,
M. Alderman,
S. Atlas,
J. Basile,
Aloysius B. Cuyjet,
...
R. Dart,
J. Felicetta,
R. Grimm,
L. Haywood,
S. Jafri,
M. Proschan,
U. Thadani,
P. Whelton,
J. Wright
|
7 |
2006 |
7
π
|
|
π
|
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
18 auth.
William C. Cushman,
C. Ford,
Jeffrey A. Cutler,
Karen L. Margolis,
Barry R Davis,
Richard H. Grimm,
Henry R. Black,
Bruce P. Hamilton,
J. Holland,
C. Nwachuku,
...
V. Papademetriou,
J. Probstfield,
Jackson T. Wright,
Michael H. Alderman,
Robert J. Weiss,
L. Piller,
Judy Bettencourt,
Sandra M. Walsh
|
6 |
2002 |
6
π
|
|
π
|
Metabolic and Clinical Outcomes in Nondiabetic Individuals With the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension
12 auth.
H. Black,
Barry J. Davis,
J. Barzilay,
C. Nwachuku,
Charles L. Baimbridge,
H. Marginean,
...
J. Wright,
J. Basile,
N. Wong,
P. Whelton,
R. Dart,
U. Thadani
|
6 |
2007 |
6
π
|
|
π
|
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial
13 auth.
F. Moll,
I. Baumgartner,
M. Jaff,
C. Nwachuku,
M. Tangelder,
G. Ansel,
George L. Adams,
T. Zeller,
J. Rundback,
M. Grosso,
...
Min Lin,
Michele F. Mercur,
E. Minar
|
6 |
2018 |
6
π
|
|
π
|
The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
11 auth.
Mahboob Rahman,
C. Brown,
J. Coresh,
B. Davis,
J. Eckfeldt,
N. Kopyt,
...
A. Levey,
C. Nwachuku,
S. Pressel,
E. Reisin,
C. Walworth
|
6 |
2004 |
6
π
|
|
π
|
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
16 auth.
T. Wun,
D. Soulières,
A. Frelinger,
L. Krishnamurti,
E. Novelli,
A. Kutlar,
K. Ataga,
C. Knupp,
L. McMahon,
J. Strouse,
...
Chunmei Zhou,
L. Heath,
C. Nwachuku,
J. Jakubowski,
J. Riesmeyer,
K. Winters
|
6 |
2013 |
6
π
|
